Company

Wiseheart Medval

Wiseheart Medval develops cell therapies for neurological diseases, including Parkinson's disease.

About

Founded in 2021 and based in Beijing, Wiseheart Medval develops cell therapies for neurological diseases and operates a GMP-grade manufacturing plant. It uses reprogramming technology to produce neural stem cells and dopaminergic neural precursor cells for potential treatment of Parkinson's disease. In January 2026, it raised over CNY 100 million in Series A funding from Beijing Jingneng Tongxin Investment Management, BCT Capital and Fuzhi Investment to advance clinical research and development.

3Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in